ODI Pharma First Quarter 2025 Earnings: kr0.096 loss per share (vs kr0.095 loss in 1Q 2024)
ODI Pharma (NGM:ODI) First Quarter 2025 Results
Key Financial Results
- Revenue: kr251.3k (down 52% from 1Q 2024).
- Net loss: kr1.47m (loss widened by 1.8% from 1Q 2024).
- kr0.096 loss per share (further deteriorated from kr0.095 loss in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
ODI Pharma shares are down 1.2% from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for ODI Pharma (1 is a bit concerning!) that we have uncovered.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:ODI
ODI Pharma
A pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe.
Flawless balance sheet with proven track record.
